VTVT Key Statistics, Chart & Performance
The current stock price of VTVT is 27.35 USD. In the past month the price increased by 7.38%. In the past year, price increased by 52.62%.
VTVT Latest News, Press Relases and Analysis
VTVT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About VTVT
Company Profile
vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. The company is headquartered in High Point, North Carolina and currently employs 23 full-time employees. The company went IPO on 2015-07-30. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.
Company Info
VTV THERAPEUTICS INC- CL A
3980 Premier Dr, Suite 310
High Point NORTH CAROLINA 27265 US
CEO: Stephen L. Holcombe
Employees: 23
Phone: 13368410300
VTV THERAPEUTICS INC- CL A / VTVT FAQ
What does VTVT do?
vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. The company is headquartered in High Point, North Carolina and currently employs 23 full-time employees. The company went IPO on 2015-07-30. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.
What is the stock price of VTV THERAPEUTICS INC- CL A today?
The current stock price of VTVT is 27.35 USD. The price decreased by -0.07% in the last trading session.
What is the dividend status of VTV THERAPEUTICS INC- CL A?
VTVT does not pay a dividend.
What is the ChartMill technical and fundamental rating of VTVT stock?
VTVT has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists VTVT stock?
VTVT stock is listed on the Nasdaq exchange.
Is VTV THERAPEUTICS INC- CL A (VTVT) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on VTVT.
What is the expected growth for VTVT stock?
The Revenue of VTV THERAPEUTICS INC- CL A (VTVT) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
VTVT Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to VTVT. When comparing the yearly performance of all stocks, VTVT is one of the better performing stocks in the market, outperforming 93.54% of all stocks.
VTVT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VTVT. While VTVT has a great health rating, there are worries on its profitability.
VTVT Financial Highlights
Over the last trailing twelve months VTVT reported a non-GAAP Earnings per Share(EPS) of -3.32. The EPS increased by 24.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -23.59% | ||
| ROE | -33.27% | ||
| Debt/Equity | 0 |
VTVT Forecast & Estimates
9 analysts have analysed VTVT and the average price target is 37.74 USD. This implies a price increase of 37.99% is expected in the next year compared to the current price of 27.35.
For the next year, analysts expect an EPS growth of -10.78% and a revenue growth -100% for VTVT